Epithelioma: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{Ammu}} | {{CMG}}; {{AE}} {{Ammu}} | ||
{{SK}} Pilomatrixoma; Calcifying Epithelioma of Malherbe | {{SK}} Pilomatrixoma; Calcifying Epithelioma of Malherbe; Epithelioma cuniculatum | ||
==Overview== | ==Overview== | ||
Epithelioma is an [[tumor|abnormal growth]] of the [[epithelium]], which is the layer of tissue that covers the surfaces of organs and other structures of the body. | Epithelioma is an [[tumor|abnormal growth]] of the [[epithelium]], which is the layer of tissue that covers the surfaces of organs and other structures of the body. |
Revision as of 15:52, 13 April 2016
WikiDoc Resources for Epithelioma |
Articles |
---|
Most recent articles on Epithelioma Most cited articles on Epithelioma |
Media |
Powerpoint slides on Epithelioma |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Epithelioma at Clinical Trials.gov Clinical Trials on Epithelioma at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Epithelioma
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Epithelioma Discussion groups on Epithelioma Patient Handouts on Epithelioma Directions to Hospitals Treating Epithelioma Risk calculators and risk factors for Epithelioma
|
Healthcare Provider Resources |
Causes & Risk Factors for Epithelioma |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Synonyms and keywords: Pilomatrixoma; Calcifying Epithelioma of Malherbe; Epithelioma cuniculatum
Overview
Epithelioma is an abnormal growth of the epithelium, which is the layer of tissue that covers the surfaces of organs and other structures of the body.
Historical Perspective
- [Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
- In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
- In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
Classification
- Epithelioma may be classified according to nature of tumor into 2 subtypes:
- Other variants of epithelioma according to the specific type of epithelial cells that are affected include basal cell carcinoma and squamous cell carcinoma.
Pathophysiology
- The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
- The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
- On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
- On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
Causes
- [Disease name] may be caused by either [cause1], [cause2], or [cause3].
- [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
- There are no established causes for [disease name].
Differentiating [disease name] from other Diseases
- [Disease name] must be differentiated from other diseases that cause
[clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
- [Differential dx1]
- [Differential dx2]
- [Differential dx3]
Epidemiology and Demographics
- The prevalence of [disease name] is approximately [number or range]
per 100,000 individuals worldwide.
- In [year], the incidence of [disease name] was estimated to be
[number or range] cases per 100,000 individuals in [location].
Age
- Patients of all age groups may develop [disease name].
- [Disease name] is more commonly observed among patients aged [age
range] years old.
- [Disease name] is more commonly observed among [elderly
patients/young patients/children].
Gender
- [Disease name] affects men and women equally.
- [Gender 1] are more commonly affected with [disease name] than
[gender 2].
- The [gender 1] to [Gender 2] ratio is approximately [number > 1] to
1.
Race
- There is no racial predilection for [disease name].
- [Disease name] usually affects individuals of the [race 1] race.
- [Race 2] individuals are less likely to develop [disease name].
Risk Factors
- Common risk factors in the development of [disease name] are [risk
factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
Natural History, Complications and Prognosis
- The majority of patients with [disease name] remain asymptomatic for
[duration/years].
- Early clinical features include [manifestation 1], [manifestation 2],
and [manifestation 3].
- If left untreated, [#%] of patients with [disease name] may progress
to develop [manifestation 1], [manifestation 2], and [manifestation 3].
- Common complications of [disease name] include [complication 1],
[complication 2], and [complication 3].
- Prognosis is generally [excellent/good/poor], and the [1/5/10year
mortality/survival rate] of patients with [disease name] is approximately [#%].
Prognosis
The prognosis varies dramatically, depending on the type and stage at the time of treatment. However, the most common epitheliomas are very easily treated and rarely result in death.
Diagnosis
Diagnostic Criteria
- The diagnosis of [disease name] is made when at least [number] of the
following [number] diagnostic criteria are met:
- [criterion 1]
- [criterion 2]
- [criterion 3]
- [criterion 4]
Symptoms
- [Disease name] is usually asymptomatic.
- Symptoms of [disease name] may include the following:
- [symptom 1]
- [symptom 2]
- [symptom 3]
- [symptom 4]
- [symptom 5]
- [symptom 6]
Physical Examination
- Patients with [disease name] usually appear [general appearance].
- Physical examination may be remarkable for:
- [finding 1]
- [finding 2]
- [finding 3]
- [finding 4]
- [finding 5]
- [finding 6]
Laboratory Findings
- There are no specific laboratory findings associated with [disease name].
- A [positive/negative] [test name] is diagnostic of [disease name].
- An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
- Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
Imaging Findings
- There are no [imaging study] findings associated with [disease name].
- [Imaging study 1] is the imaging modality of choice for [disease name].
- On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
- [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
Other Diagnostic Studies
- [Disease name] may also be diagnosed using [diagnostic study name].
- Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
Treatment
Treatment usually involves surgically removing the tumor and affected tissue.
Medical Therapy
- There is no treatment for [disease name]; the mainstay of therapy is supportive care.
- The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
- [Medical therapy 1] acts by [mechanism of action1].
- Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
Surgery
- Surgery is the mainstay of therapy for [disease name].
- [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
- [Surgical procedure] can only be performed for patients with [disease stage] [disease name].
Prevention
- There are no primary preventive measures available for [disease name].
- Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
- Once diagnosed and successfully treated, patients with [disease name] are followedup every [duration]. Followup testing includes [test 1], [test 2], and [test 3].
References
Template:Tumors of bone, cartilage, skin, connective, and soft tissue